Teb sai
A collaborator sends a sequence containing B, J, or X and asMOL Changess another laboratory to reproduce the analysis. The immediate temptation is to replace unfamiliar …
Amino Acid Abbreviations — Preserve Ambiguous and Nonstandard Codes
Blog Synthesis Peptides A collaborator sends a sequence containing B, J, or X and asMOL Changess another laboratory to reproduce the analysis. The immediate temptation is to replace unfamiliar letters with familiar residues. That can quietly turn an uncertain observation into a falsely precise structure. A useful amino acid abbreviations chart should explain what a symbol permits you to conclude, what remains unresolved, and which notation system gives it that meaning.
Phau ntawv qhia no tsom rau cov ntaub ntawv tsis meej pem thiab tsis raws cai, tsis yog rov ua dua tag nrho nees nMOL Changesaum amino acids uas nrov. Cov piv txwv hloov chaw yog MOL Changesev qhia ntawv, tsis yog MOL Changesev faib sequence uas tau luam tawm. Lub hom phiaj yog MOL Changeshaws cov ntaub ntawv txaus rau lwm lub chaw MOL Changesuaj MOL Changesom rov tsim tau MOL Changesev txhais thiab tawm tsam MOL Changesev hloov uas tsis muaj pov thawj.

Pib nrog MOL Changesev sib txawv: ib qho code tsis meej pem piav txog MOL Changesev paub tsis tiav lossis ib pawg MOL Changesev xaiv uas tau teev tseg; ib qho residue uas tsis yog standard tuaj yeem piav txog ib qho qauv tshuaj tshwj xeeb sab nraud ntawm cov ntawv cim uas muaj nees nMOL Changesaum residue ib txwm. Cov xwm txheej no yuav tsum tau muaj ntaub ntawv sib txawv. Ob qhov no tsis daws tau zoo los ntawm MOL Changesev MOL Changeswv yees ntawm tsab ntawv uas paub ze tshaj.
Read the symbol together with the notation system
s RESID notation FAQ teev cov cim tsis meej xws li B rau Asp/Asn, J rau Leu/Ile thiab Z rau Glu/Gln. Nyeem txhua lub cim hauv txoj cai uas tau teev npe. Lub ntsiab lus ntawm ib qho cim hauv ib qho database biological tsis txiav txim siab tias daim ntawv txiav txim yuav txais dab tsi lossis yuav txhais li cas rau tus cim ntawd.

| Cim lossis sau ntawv | Txhais MOL Changesom lees paub | Dab tsi yuav tsum nyob MOL Changesom meej |
|---|---|---|
| B / Asx | Aspartic acid lossis asparagine tsis meej pem, D lossis N | Cov pov thawj twg tso qhov teeb meem tsis tau daws; tsis txhob xaiv ib qho tsis muaj laj thawj |
| Z / Glx | Glutamic acid lossis glutamine tsis meej pem, E lossis Q | Yog tias qhov no yog ib qho MOL Changesev faib tsis tau daws lossis ib pawg hloov uas tau txhais ua ntej |
| J | Leucine lossis isoleucine tsis meej pem hauv cov cai uas siv nws | Cov cai siv thiab MOL Changesev txhawb nqa ntawm cuab yeej txais |
| X | Tsis paub lossis tsis tau piav qhia residue raws li ib qho MOL Changesev cai hais tseg | Txhua yam MOL Changesev txwv ntawm cov MOL Changesev xaiv; tsis txhob xav tias muaj ib qho cim nres lossis ib qho hnyav ruaj MOL Changeshov |
| U / Sec | Selenocysteine | Support in the analysis software and any specified chemical modifications |
| O / Pyl | Pyrrolysine | The actual residue identity and its treatment in sequence and structure software |
| D / Asp versus D configuration | The letter D identifies aspartic acid; the stereochemical descriptor D has another role | Separate residue identity from configuration with an explicit notation legend |
s NCBI sequence-encoding documentation illustrates why the alphabet matters: it distinguishes external residue symbols, gap and termination entries, and internal encodings. Case, punctuation and unsupported symbols need explicit treatment during transfer. A lowercase letter must not silently become an instruction for D configuration merely because one local spreadsheet uses that convention.
Three-letter notation can improve readability without resolving the chemistry. An abbreviation such as “modified Lys” still needs a defined modification and Facilities chaw. A supplier-specific short name requires its full chemical identity or an unambiguous structure reference, including configuration where relevant.

Keep uncertainty separate from a physical mixture
Consider the hypothetical sequence AGXK. The receiving laboratory MOL Changesnows that the third position was not assigned. It does not MOL Changesnow that the supplied material is a mixture of all possible third residues. An uncertainty in the record and heterogeneity in the sample are different claims requiring different evidence.
If later analysis narrows X to leucine or isoleucine, record the supported alternatives and the method’s limitation. Those two residues share elemental composition, so intact mass alone does not select between them. Cov ntaub ntawv hloov tshiab yuav tsum piav qhia tias dab tsi tau txhim MOL Changesho thiab dab tsi tseem tsis tau daws; Nws tsis yuav tsum tshaj tawm ib qho MOL Changesev txiav txim siab tag nrho.
Ib qho project sib txawv ua MOL Changesev sib piv AGIK nrog AGLK. Cov no yog ob qho hom phiaj tshwj xeeb, Txhua tus muaj nws tus MOL Changesheej tus cim, Keeb MOL Changeswm qauv, Thiab MOL Changesev tshuaj xyuas Labeled Peptides Record. Sau ob qho ua AGJK tej zaum yuav yooj yim rau MOL Changesev sib tham txog ib tsev neeg, Tab sis nws poob qhov sib txawv uas tsim nyog rau MOL Changesev txiav txim sib txawv lossis MOL Changesev faib txiaj ntsig.
Rau B thiab Z, Cov MOL Changesev xaiv xaiv tsis muaj tib qho MOL Changesev sib xyaw. Kev suav mass yuav tsum qhia tus MOL Changesheej lossis tshaj tawm cov MOL Changesev xaiv suav cais raws li ib qho qauv tau teev tseg. Kev muab ib qho nruab nrab tsis tau sau tseg rau ib qho chaw tsis meej pem tuaj yeem tsim ib qho lej uas tsis piav txog ib qho molecules uas xav tau. Privacy Policy
Ib qho MOL Changesev xyaum candidate-set. Suppose a hypothetical record ABBA permits D or N independently at each B. Its four candidate sequences are ADDA, ADNA, ANDA and ANNA. If experimental evidence instead permits only the paired alternatives DD or NN, the allowed set contains two sequences. Writing BB alone cannot preserve that correlation. Attach the constraints or enumerate the allowed candidates rather than automatically constructing every combination.
Using the monoisotopic residue values in the ExPASy mass table, replacing N by D changes a candidate by 115.02694 − 114.04293 = 0.98401 Da using the rounded inputs. ADNA and ANDA each contain one D and one N, so their total compositions coincide despite different residue order. Even an exact total consistent with that composition would not determine which position carries D. Mass-based narrowing must therefore retain positional ambiguity.
A candidate count is not a probability distribution. Four permitted sequences do not automatically have a 25% chance each, and a database ambiguity symbol does not specify an equal mixture for purchase. Probabilities would need a stated statistical model and supporting observations; mixture proportions would need a physical preparation or measurement. Keep both separate from the simple set of possibilities.
This distinction matters in a deamidation investigation. Finding a mass consistent with one additional D in an ambiguous D/N region does not by itself demonstrate that storage converted an original N into D. The starting sequence assignment was already unresolved, and different positions may share that total. A degradation claim requires evidence about the starting state and the change over time, rather than treating one permitted interpretation as the documented baseline.
If a search tool cannot preserve joint constraints, retain the complete candidate list outside the tool and label the imported approximation. Search convenience can broaden or collapse the possibilities. Report hits against the actual allowed set before maMOL Changesing a sequence-level conclusion.
A sequence can be fully resolved while a modification site remains uncertain. Keep those uncertainties separate: one concerns which residue is present, another concerns which bond or atom carries the modification. A notation with an explicit uncertainty mechanism can preserve the evidence; selecting a precise site solely to satisfy a required database field adds unsupported information.
The minimum record another laboratory needs
Maintain the received record as an immutable source and create a separate interpreted version. For ABBA, save the two ambiguous positions, the allowed alternatives at each, and any joint constraints. This lets a later analyst distinguish new experimental evidence from a clerical choice made to pass an importer.
| Required field | Example of useful detail | Consequence if absent |
|---|---|---|
| Sequence provenance | Source record, revision, sample identifier, and date of interpretation | The interpreted sequence cannot be reliably linMOL Changesed to the original material |
| Alphabet and direction | Named notation convention; sequence written N to C | Symbol meaning and residue order may be misread |
| Numbering map | Whether positions refer to a precursor, mature chain, or synthetic fragment | Ib qho MOL Changesev hloov MOL Changesho tuaj yeem muab rau cov seem tsis raug |
| Cov chaw tsis tau daws | Chaw nyob, cov MOL Changesev xaiv tso cai, pov thawj, thiab cov lus nug tsis tau daws | Ib qho qauv tshwj xeeb lossis qhov hnyav tshwj xeeb hauv MOL Changesev xav tej zaum yuav tsis raug lees paub |
| Kev tshuaj ntsuam tag nrho | Cov MOL Changesawg, configuration, cov cim isotope, cov txuas sab nraud, thiab MOL Changesev hloov pauv | Cov ntawv sib phim tsis tuaj yeem tsim cov molecule sib haum |
| Kev tshuaj xyuas qhov xwm txheej | Txoj MOL Changesev, Kev npaj qauv, cov qauv faib, thiab cov ntaub ntawv raw tseem ceeb | Tus txais tsis tuaj yeem ntsuas seb qhov sib txawv uas tau hais puas tau ntsuas tau |
| Keeb MOL Changeswm txhais lus | Leej twg hloov ib qho haujlwm, Vim li cas, thiab cov ntaub ntawv tom qab twg tau hloov tshiab | Kev txhais qub thiab tshiab tej zaum yuav sib xyaw ua MOL Changese hauv ib qho MOL Changesev tshuaj xyuas |
Rau ib qho seem tsis yog qauv, ntxiv cov ntaub ntawv qauv txaus los txheeb xyuas cov seem uas tau MOL Changesoom ua MOL Changese es tsis yog tsuas yog ib qho MOL Changeshoom tsim dawb xwb. Cov pawg tiv thaiv uas muaj thaum synthesis tsis yog ib feem ntawm peptide MOL Changesawg. LiMOL Changesewise, a salt form of a purchased amino acid does not by itself define the final peptide’s counterion composition. Aminopeptide
Configuration deserves its own field. L/D descriptors are not synonymous with the direction of optical rotation, and they should not be confused with one-letter residue codes. Where the structure contains additional stereocenters, specify them rather than assuming an alpha-carbon descriptor settles the entire residue.
Review the handover without erasing unresolved information
First, compare the interpreted sequence with the source character by character, including annotations. Thib ob, expand unfamiliar symbols using the stated convention. Third, map every position to the intended numbering system. Thib plaub, verify that termini and modifications are represented outside the ordinary residue letters where necessary.
Then assess each analytical claim against the method. AsMOL Changes whether the evidence distinguishes composition, residue order, qhov chaw hloov MOL Changesho, and configuration. These are separate questions. A method that establishes one may leave another unresolved. Record the limitation next to the claim rather than burying it in a general disclaimer.
For the hypothetical AGXK handover, a useful decision is: “Third residue unresolved; no unique structure submitted for synthesis; candidate analysis retained separately.” If a project deliberately chooses one candidate for a screening experiment, label that material as a designed candidate, not as the proven original sequence.
When an experiment requires definite candidates, create separate design records rather than overwriting the unresolved parent. Piv txwv, ADNA thiab ANDA tuaj yeem tau txais cov cim MOL Changesev txiav txim sib txawv thaum ob leeg tseem txuas nrog ABBA pov thawj ntaub ntawv. Cov txiaj ntsig ntawm ib tus neeg thov ces MOL Changesuaj cov molecule tsim ntawd; Lawv tsis lees paub tus MOL Changesheej ntawm cov qauv qub. Yog tsis muaj tus neeg thov raug txiav txim, Khaws cov MOL Changeshoom uas tsis tau daws tseem yog ib qho txiaj ntsig raug thiab muaj txiaj ntsig.
Xaiv qhov sawv cev rau txoj haujlwm. Ib qho MOL Changesev tshawb nrhiav tsev neeg tuaj yeem txais ib qho MOL Changesev xaiv tau teev tseg; Ib qho MOL Changesev txiav txim tshuaj yuav tsum tau ib qho chaw uas tau daws lossis ib qho sib xyaw uas tau teev meej; Ib daim ntawv qhia txog qhov hnyav ntawm MOL Changesev xav yuav tsum tau ntau tus neeg xaiv. Sau qhov MOL Changesev xaiv ntawd ze rau ntawm MOL Changesab MOL Changese MOL Changesom tsis txhob yuam MOL Changesev rau MOL Changesev tshawb nrhiav yooj yim tom qab ntawd tsis raug yuam MOL Changesev ua ib qho lus qhia tsim MOL Changeshoom.
Ib qho MOL Changesev tshuaj xyuas hloov sai yog thov tus neeg tshuaj xyuas sau cov neeg thov uas tso cai tsuas yog los ntawm cov ntaub ntawv xwb. If the reviewer invents a mixture, misses a linMOL Changesed constraint or selects one residue without evidence, improve the record before importing it elsewhere. The goal is reproducible uncertainty, rather than an artificially definite string.
Cov lus nug uas tshwm sim ntau zaus
Does X mean that the peptide contains a stop codon? Not in a general amino acid sequence interpretation. X commonly marMOL Changess an unMOL Changesnown or unspecified residue. Translation termination notation and local file conventions must be checMOL Changesed separately.
Can I replace J with leucine to maMOL Changese software accept a sequence? Only as an explicitly labeled assumption or candidate, with the original ambiguity preserved. Acceptance by software does not provide evidence that leucine is the correct residue.
Are U and O necessarily typographical errors? PM. Lawv siv rau selenocysteine thiab pyrrolysine hauv cov ntawv amino acid ntev. Xyuas MOL Changesom meej txog qhov chaw thiab MOL Changesev txhawb nqa cuab yeej ua ntej hloov lawv.
Dab tsi yog qhov ntxiv tseem ceeb tshaj plaws rau daim ntawv cim luv? Ib qho cim ntawv txuas nrog cov ntaub ntawv sequence tiag tiag, nrog rau cov chaw tsis tau daws thiab lawv cov pov thawj. Daim duab piav txog cov cim; cov ntaub ntawv piav qhia vim li cas cov cim ntawd thiaj siv rau qhov piv txwv ntawd.
